ATNF

180 Life Sciences Corp.

0.27 USD

Last updated Dec 4, 00:01 UTC

Yesterday HIGH

$0.33

Yesterday LOW

$0.26

52w HIGH

$9.82

52w LOW

$0.26

EPS

-1.29

PE

-0.21

Next Earnings

Apr 1, 2024

Overview News Government Trades

180 Life Sciences Corp. stock is down -36.98% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 December’s closed higher than November.

1180 Life Sciences Corp. develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

180lifesciences.com

Lisa Levin

Thu Aug 10, 2023

Why AppLovin Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket

Gainers PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) shares surged 46.7% to $0.64 in pre-market trading after gaining 6% on Wednesday.
Benzinga Insights

Wed Aug 9, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Lisa Levin

Wed Aug 9, 2023

Why EMCORE Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Gainers 180 Life Sciences Corp. (NASDAQ: ATNF) shares surged 109.2% to $1.58 in pre-market trading after falling over 6% on Tuesday.
Benzinga Insights

Tue Aug 8, 2023

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's trading, 188 companies set new 52-week lows.
Vuk Zdinjak

Mon Aug 7, 2023

180 Life Sciences Teams Up With Hadassah Hospital To Test A New Formulation Of CBD For Enhanced Oral Uptake

180 Life Sciences Corp.
Benzinga Newsdesk

Mon Aug 7, 2023

180 Life Sciences Announces An Agreement For A Clinical Pharmacology Study Testing A New Formulation Of CBD For Enhanced Oral Uptake
Benzinga Insights

Thu Aug 3, 2023

Stocks That Hit 52-Week Lows On Thursday

During Thursday's session, 92 stocks hit new 52-week lows.
Happy Mohamed

Thu Aug 3, 2023

180 Life Sciences Provides Update On Regulatory Approval Process In The UK And U.S. For Dupuytren's Disease Treatment; Continues Consultations With The UK MHRA And Initiates A Type C Meeting Request With the U.S. FDA

180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in
Vuk Zdinjak

Mon Jul 31, 2023

180 Life Sciences Files A Provisional Patent For CBD-Based Appetite Suppressant

180 Life Sciences Corp. (NASDAQ: ATNF) filed a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon related peptide-1 (GLP-1) agonists to address the problem of obesity and wei
Happy Mohamed

Mon Jul 31, 2023

180 Life Sciences Corp. Announces The Filing Of A Provisional Patent Describing The Combination Of CBD With GLP-1 Agonists To Suppress Appetite

180 Life Sciences Corp. (NASDAQ:ATNF) ("180LS" or the "Company"), today announced the filing of a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon

RIOT $13.78 USD

EGLE $47.87 USD

GLD $192.07 USD

MI MI $0.18 USD

BOND $90.00 USD

SILJ SILJ $10.08 USD

MSTR $527.86 USD